Published in Mol Cell Biol on August 01, 2004
A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev (2006) 2.76
Full antagonism of the estrogen receptor without a prototypical ligand side chain. Nat Chem Biol (2016) 2.05
Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci (2008) 1.81
Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am J Pathol (2010) 1.73
The Yin and Yang of YY1 in the nervous system. J Neurochem (2008) 1.68
ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med (2011) 1.47
Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol Endocrinol (2008) 1.40
Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta (2008) 1.36
Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC Genomics (2011) 1.28
The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene. Oncogene (2005) 1.21
Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. Mol Endocrinol (2011) 1.21
Identification of a hormone-regulated dynamic nuclear actin network associated with estrogen receptor alpha in human breast cancer cell nuclei. Mol Cell Proteomics (2010) 1.19
Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc. Mol Cell Biol (2009) 1.16
Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes. PLoS One (2012) 1.09
RSK in tumorigenesis: connections to steroid signaling. Steroids (2010) 1.08
Retracted IKKepsilon phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer. J Biol Chem (2009) 1.07
Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. Elife (2014) 1.07
Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos. Mol Endocrinol (2005) 1.06
Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element. Nucleic Acids Res (2010) 1.06
Prolactin signals via Stat5 and Oct-1 to the proximal cyclin D1 promoter. Mol Cell Endocrinol (2005) 1.06
Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol (2010) 1.06
Time-course analysis of genome-wide gene expression data from hormone-responsive human breast cancer cells. BMC Bioinformatics (2008) 1.05
Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells. BMC Cancer (2012) 1.02
Cyclin D1 is transcriptionally down-regulated by ZO-2 via an E box and the transcription factor c-Myc. Mol Biol Cell (2007) 1.02
The oncogenic role of Yin Yang 1. Crit Rev Oncog (2011) 1.02
HEXIM1 regulates 17beta-estradiol/estrogen receptor-alpha-mediated expression of cyclin D1 in mammary cells via modulation of P-TEFb. Cancer Res (2008) 1.01
ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells. Mol Cell Biol (2011) 1.00
Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol (2015) 0.98
Genome-wide computational analysis of dioxin response element location and distribution in the human, mouse, and rat genomes. Chem Res Toxicol (2011) 0.96
Progesterone receptors, their isoforms and progesterone regulated transcription. Mol Cell Endocrinol (2011) 0.92
Molecular determinants of context-dependent progesterone receptor action in breast cancer. BMC Med (2014) 0.92
Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts. Oncogene (2008) 0.90
Post-transcriptional regulation of human breast cancer cell proteome by unliganded estrogen receptor β via microRNAs. Mol Cell Proteomics (2014) 0.89
1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (p,p'-DDE) disrupts the estrogen-androgen balance regulating the growth of hormone-dependent breast cancer cells. Breast Cancer Res (2008) 0.89
Role of phosphorylation in progesterone receptor signaling and specificity. Mol Cell Endocrinol (2011) 0.88
Research resource: progesterone receptor targetome underlying mammary gland branching morphogenesis. Mol Endocrinol (2013) 0.87
Chronic cadmium exposure stimulates SDF-1 expression in an ERα dependent manner. PLoS One (2013) 0.87
RAC3 is a pro-migratory co-activator of ERα. Oncogene (2011) 0.86
A Common Docking Domain in Progesterone Receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells. Nucleic Acids Res (2013) 0.85
BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact? Int J Biol Sci (2014) 0.84
Co-treatment of mouse antral follicles with 17β-estradiol interferes with mono-2-ethylhexyl phthalate (MEHP)-induced atresia and altered apoptosis gene expression. Reprod Toxicol (2014) 0.83
Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. Breast Cancer Res (2013) 0.83
The contribution of 17beta-hydroxysteroid dehydrogenase type 1 to the estradiol-estrone ratio in estrogen-sensitive breast cancer cells. PLoS One (2012) 0.82
Breaking the cycle: An insight into the role of ERα in eukaryotic cell cycles. J Carcinog (2011) 0.81
Estrogen receptor α-coupled Bmi1 regulation pathway in breast cancer and its clinical implications. BMC Cancer (2014) 0.80
YY1 regulates melanoma tumorigenesis through a miR-9 ~ RYBP axis. J Exp Clin Cancer Res (2015) 0.80
The elements of human cyclin D1 promoter and regulation involved. Clin Epigenetics (2011) 0.79
Transcription regulator Yin-yang 1: from silence to cancer. Crit Rev Oncog (2011) 0.78
Identification and characterization of novel and conserved microRNAs in several tissues of the Chinese rare minnow (Gobiocypris rarus) based on illumina deep sequencing technology. BMC Genomics (2016) 0.78
Enhanced LH action in transgenic female mice expressing hCGbeta-subunit induces pituitary prolactinomas; the role of high progesterone levels. Endocr Relat Cancer (2010) 0.78
Effects of the lifestyle habits in breast cancer transcriptional regulation. Cancer Cell Int (2016) 0.76
Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming. Mol Cancer Res (2015) 0.76
Acetylation at lysine 183 of progesterone receptor by p300 accelerates DNA binding kinetics and transactivation of direct target genes. J Biol Chem (2013) 0.76
CDC2 mediates progestin initiated endometrial stromal cell proliferation: a PR signaling to gene expression independently of its binding to chromatin. PLoS One (2014) 0.75
A new method for sequencing DNA. Proc Natl Acad Sci U S A (1977) 250.51
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res (1983) 124.30
The nuclear receptor superfamily: the second decade. Cell (1995) 24.99
Cancer cell cycles. Science (1996) 21.29
The retinoblastoma protein and cell cycle control. Cell (1995) 20.21
Gene regulation by steroid hormones. Cell (1989) 12.96
The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev (2000) 11.65
Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell (2000) 11.10
Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell (2003) 10.42
A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell (2003) 9.81
The ubiquitous octamer-binding protein Oct-1 contains a POU domain with a homeo box subdomain. Genes Dev (1988) 8.11
Specific protection against breast cancers by cyclin D1 ablation. Nature (2001) 6.94
Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell (1995) 6.08
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (1994) 5.34
Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev (1995) 4.64
Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell (2000) 4.48
S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell (2003) 4.03
Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol (2000) 3.96
CDK-independent activation of estrogen receptor by cyclin D1. Cell (1997) 3.85
The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol (2000) 3.43
Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene (1999) 3.29
Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem (2001) 3.07
p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. Genes Dev (1998) 2.96
Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med (1995) 2.74
Regulation of transcription factor YY1 by acetylation and deacetylation. Mol Cell Biol (2001) 2.72
Linking cyclins to transcriptional control. Gene (2002) 2.49
Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem (1997) 2.40
Mitotic phosphorylation of the Oct-1 homeodomain and regulation of Oct-1 DNA binding activity. Science (1991) 2.27
Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc Natl Acad Sci U S A (1999) 2.19
Inducible regulatory elements in the human cyclin D1 promoter. Oncogene (1994) 2.16
Interaction of protein with DNA in vitro. Methods Enzymol (1987) 2.07
Minireview: nuclear receptor coactivators--an update. Endocrinology (2002) 2.04
17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene (1996) 2.01
Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem (1999) 2.00
c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol (1998) 1.97
Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem (2002) 1.95
Functional antagonism between YY1 and the serum response factor. Mol Cell Biol (1992) 1.91
17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol (2000) 1.83
Retracted Nuclear receptor function requires a TFTC-type histone acetyl transferase complex. Mol Cell (2002) 1.75
Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol (1996) 1.75
Differential phosphorylation of the transcription factor Oct1 during the cell cycle. Science (1991) 1.74
Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol (1993) 1.65
Relief of YY1-induced transcriptional repression by protein-protein interaction with the nucleolar phosphoprotein B23. J Biol Chem (1994) 1.55
Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem (2001) 1.55
Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. Biochim Biophys Acta (2001) 1.54
Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor. Nucleic Acids Res (1990) 1.44
A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol (2004) 1.35
AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Cancer Res (2001) 1.35
A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J Biol Chem (2000) 1.34
Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J Biol Chem (1998) 1.26
The nuclear factor YY1 suppresses the human gamma interferon promoter through two mechanisms: inhibition of AP1 binding and activation of a silencer element. Mol Cell Biol (1996) 1.26
Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo. Endocrinology (1997) 1.26
Characterization of the physical interaction between estrogen receptor alpha and JUN proteins. J Biol Chem (2001) 1.17
Estrogen regulation of proto-oncogenes coding for nuclear proteins. Crit Rev Oncog (1993) 1.16
Octamer factors exert a dual effect on the IL-2 and IL-4 promoters. J Immunol (1994) 1.09
Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer. Eur J Cancer (1990) 1.08
Interaction of Oct-1 with TFIIB. Implications for a novel response elicited through the proximal octamer site of the lipoprotein lipase promoter. J Biol Chem (1995) 1.02
Modulation of AP-1 activity by the human progesterone receptor in endometrial adenocarcinoma cells. Proc Natl Acad Sci U S A (1996) 1.02
Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens. Cancer Res (1998) 1.00
Oct-1 potentiates CREB-driven cyclin D1 promoter activation via a phospho-CREB- and CREB binding protein-independent mechanism. Mol Cell Biol (2002) 0.98
The retinoblastoma-interacting zinc-finger protein RIZ is a downstream effector of estrogen action. Proc Natl Acad Sci U S A (2000) 0.97
Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells. J Steroid Biochem Mol Biol (1998) 0.95
17 beta-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation. Oncogene (1996) 0.93
Rb interacts with TAF(II)250/TFIID through multiple domains. Oncogene (1997) 0.91
Isolation and characterization of the human nucleophosmin/B23 (NPM) gene: identification of the YY1 binding site at the 5' enhancer region. Nucleic Acids Res (1997) 0.88
Differential expression of the human ST5 gene in HeLa-fibroblast hybrid cell lines mediated by YY1: evidence that YY1 plays a part in tumor suppression. Nucleic Acids Res (1996) 0.85
The antiestrogen ICI 182,780 inhibits proliferation of human breast cancer cells by interfering with multiple, sequential estrogen-regulated processes required for cell cycle completion. Mol Cell Endocrinol (2000) 0.84
A novel transcriptional element which regulates expression of the CYP2D4 gene by Oct-1 and YY-1 binding. Biochim Biophys Acta (2003) 0.79
Two distinct factors bind to the rabbit uteroglobin TATA-box region and are required for efficient transcription. Mol Cell Biol (1994) 0.78
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science (2008) 3.09
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med (2004) 2.72
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med (2004) 2.71
PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell (2010) 2.50
Homeodomain-mediated beta-catenin-dependent switching events dictate cell-lineage determination. Cell (2006) 2.40
Whole-genome bisulfite sequencing of two distinct interconvertible DNA methylomes of mouse embryonic stem cells. Cell Stem Cell (2013) 2.32
Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov (2007) 1.91
HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A (2008) 1.80
Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am J Pathol (2010) 1.73
TBL1 and TBLR1 phosphorylation on regulated gene promoters overcomes dual CtBP and NCoR/SMRT transcriptional repression checkpoints. Mol Cell (2008) 1.65
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther (2010) 1.62
"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology (2009) 1.59
Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. Cell Cycle (2009) 1.57
Quantitative expression profiling of highly degraded RNA from formalin-fixed, paraffin-embedded breast tumor biopsies by oligonucleotide microarrays. Lab Invest (2008) 1.51
Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem (2005) 1.51
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One (2011) 1.44
Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep (2009) 1.39
A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol (2004) 1.35
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist (2010) 1.35
Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC Genomics (2011) 1.28
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther (2013) 1.26
Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med (2004) 1.25
Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol (2008) 1.21
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood (2013) 1.19
Identification of a hormone-regulated dynamic nuclear actin network associated with estrogen receptor alpha in human breast cancer cell nuclei. Mol Cell Proteomics (2010) 1.19
Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement. Stem Cells (2014) 1.19
Trials with 'epigenetic' drugs: an update. Mol Oncol (2012) 1.19
Conditions suggesting lymphoma: case 2. Mediastinal liposarcoma in a patient with previous testicular cancer. J Clin Oncol (2005) 1.15
Sirtuins and disease: the road ahead. Front Pharmacol (2012) 1.15
epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors. J Med Chem (2008) 1.13
ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood (2012) 1.12
Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. J Cell Biochem (2005) 1.10
Nε-lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart. Proc Natl Acad Sci U S A (2011) 1.09
Comparative genome-wide DNA methylation analysis of colorectal tumor and matched normal tissues. Epigenetics (2012) 1.08
Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS One (2010) 1.08
Bispyridinium dienes: histone deacetylase inhibitors with selective activities. J Med Chem (2007) 1.08
Mitogen-activated protein kinases and NF-kappa B are involved in TNF-alpha responses to group B streptococci. J Immunol (2002) 1.07
Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res (2008) 1.07
Retinoic acid impairs estrogen signaling in breast cancer cells by interfering with activation of LSD1 via PKA. Biochim Biophys Acta (2013) 1.07
Molecular identification of ERalpha-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes. J Cell Physiol (2004) 1.06
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol (2009) 1.06
Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase. PLoS One (2012) 1.06
Time-course analysis of genome-wide gene expression data from hormone-responsive human breast cancer cells. BMC Bioinformatics (2008) 1.05
Distinct nongenomic signal transduction pathways controlled by 17beta-estradiol regulate DNA synthesis and cyclin D(1) gene transcription in HepG2 cells. Mol Biol Cell (2002) 1.05
Specific inhibition of NF-Y subunits triggers different cell proliferation defects. Nucleic Acids Res (2011) 1.04
Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia. Blood (2012) 1.02
HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochim Biophys Acta (2008) 1.02
Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. J Med Chem (2006) 1.02
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol (2004) 1.01
Epigenetic alteration of microRNAs in DNMT3B-mutated patients of ICF syndrome. Epigenetics (2010) 0.99
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. Sci Rep (2015) 0.99
Concentration of circulating endothelial progenitor cells (EPC) in normal pregnancy and in pregnant women with diabetes and hypertension. Am J Obstet Gynecol (2007) 0.98
Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem (2006) 0.98
HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. J Mol Endocrinol (2010) 0.98
Synthesis and biological validation of novel synthetic histone/protein methyltransferase inhibitors. ChemMedChem (2007) 0.97
Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. Mol Pharmacol (2007) 0.97
Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. J Med Chem (2009) 0.97
The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches. Expert Rev Hematol (2013) 0.97
Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392. Cancer Res (2014) 0.96
Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues. J Med Chem (2010) 0.96
Prostaglandin E2 induces interleukin-8 gene transcription by activating C/EBP homologous protein in human T lymphocytes. J Biol Chem (2005) 0.96
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. J Med Chem (2012) 0.96
Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells. Stem Cells Dev (2009) 0.95
Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin Pharmacother (2010) 0.94
Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells. Biochimie (2012) 0.94
Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma. Biochem Biophys Res Commun (2013) 0.94
Effects of oestrogen on microRNA expression in hormone-responsive breast cancer cells. Horm Cancer (2012) 0.93
Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother Pharmacol (2005) 0.93
Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile. Bioorg Med Chem (2011) 0.92
Identification of proteins associated with ligand-activated estrogen receptor α in human breast cancer cell nuclei by tandem affinity purification and nano LC-MS/MS. Proteomics (2010) 0.92
The effect of two different protocols of potassium haemodiafiltration on QT dispersion. Nephrol Dial Transplant (2005) 0.92
Desacyl-ghrelin and synthetic GH-secretagogues modulate the production of inflammatory cytokines in mouse microglia cells stimulated by beta-amyloid fibrils. J Neurosci Res (2009) 0.91
Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors. Mol Cancer Ther (2008) 0.91
MSX1 and TGF-beta3 are novel target genes functionally regulated by FOXE1. Hum Mol Genet (2010) 0.91
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. J Med Chem (2013) 0.91
Role of osteopontin in breast cancer patients. Tumori (2009) 0.91
Pseudomonas aeruginosa induces interleukin-8 (IL-8) gene expression in human conjunctiva through the recruitment of both RelA and CCAAT/enhancer-binding protein beta to the IL-8 promoter. J Biol Chem (2008) 0.91
Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer (2012) 0.90
A large set of estrogen receptor β-interacting proteins identified by tandem affinity purification in hormone-responsive human breast cancer cell nuclei. Proteomics (2010) 0.90
Histone acetyltransferase inhibitors and preclinical studies. Expert Opin Ther Pat (2009) 0.90
Cannabinoid receptor 1 influences chromatin remodeling in mouse spermatids by affecting content of transition protein 2 mRNA and histone displacement. Endocrinology (2010) 0.90
Identification of genes involved in growth inhibition of breast cancer cells transduced with estrogen receptor. FEBS Lett (2003) 0.89
Post-transcriptional regulation of human breast cancer cell proteome by unliganded estrogen receptor β via microRNAs. Mol Cell Proteomics (2014) 0.89
Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. Bioorg Med Chem Lett (2008) 0.89
Endocannabinoid control of sperm motility: the role of epididymus. Gen Comp Endocrinol (2007) 0.89